Global Cell and Gene Therapy CDMO Market — Intelligence Report

The global cell and gene therapy CDMO market has moved from a specialist outsourcing niche into a strategic manufacturing backbone for advanced therapeutics. Nexvora Intelligence estimates the market at approximately $•••–••• billion in 2025, supported by rising clinical pipeline density, increasing commercial product launches, and the persistent complexity of viral vector, plasmid DNA, cell processing, fill-finish, and analytical testing workflows. The sector remains capacity-constrained in several high-value segments, but the imbalance is shifting from broad scarcity toward differentiated demand for proven quality systems, late-stage readiness, and scalable platforms.

Growth is being driven by the transition of cell and gene therapies from early innovation programs into commercially managed assets. Sponsors are increasingly outsourcing to reduce capital intensity, accelerate time-to-clinic, access specialized manufacturing know-how, and mitigate technical execution risk. Nexvora Intelligence models the market to expand at a ••%–••% CAGR through 2032, reaching approximately $•••–••• billion by the end of the forecast period, with upside tied to successful late-stage approvals, broader reimbursement acceptance, and manufacturing yield improvements.

Viral vector manufacturing remains one of the most strategically important segments, particularly for adeno-associated virus and lentiviral vector production. However, the market is becoming more selective: sponsors are prioritizing CDMOs with demonstrated process development capability, regulatory inspection readiness, robust analytical platforms, and the ability to support comparability requirements as programs scale. Plasmid DNA, cell therapy manufacturing, and specialized fill-finish services are also gaining importance as sponsors seek integrated supply chains rather than fragmented vendor networks.

The competitive landscape is bifurcating between large global CDMOs with end-to-end infrastructure and specialized providers focused on high-complexity modalities. Scale alone is no longer sufficient; buyers are increasingly evaluating execution track record, tech transfer discipline, batch success rates, release-testing timelines, regulatory documentation quality, and commercial supply resilience. This is creating pricing power for top-tier providers while exposing underutilized or technically weaker capacity to margin pressure.

Nexvora Intelligence developed this opening market view using proprietary demand modeling, therapy pipeline segmentation, modality-level manufacturing intensity assumptions, and CDMO service revenue mapping across preclinical, clinical, and commercial phases.

Market sizing reflects modeled estimates only and incorporates assumptions for viral vector production, plasmid DNA supply, cell therapy manufacturing, analytical services, process development, fill-finish, and related quality and regulatory support.

Forecast ranges account for approval velocity, clinical attrition, capacity utilization, pricing pressure, commercial scale-up timing, regional outsourcing penetration, and shifts between captive and outsourced manufacturing models.

All figures are Nexvora Intelligence modeled estimates and should be interpreted as directional market intelligence rather than externally sourced reported statistics.